Blueprint Medicines (Germany) GmbH

EFPIA Transparency Reporting

Methodological Notes

June 30, 2026

Table of Contents

Introduction

In 2014, the European Federation of Pharmaceutical Industries and Associations (EFPIA) introduced disclosure requirements to promote transparency in the pharmaceutical industry. Blueprint Medicines fully supports this initiative and values its collaboration with healthcare professionals (HCPs) and healthcare organizations (HCOs).

These methodological notes explain how Blueprint Medicines interprets and implements the requirements of the EFPIA Transparency Code.

This disclosure is prepared in accordance with the German Transparency Code of the FSA (Freiwillige Selbstkontrolle für die Arzneimittelindustrie e.V.), which implements the EFPIA Transparency Code in Germany. For simplicity, the following sections refer only to the EFPIA Transparency Code.

1 Definitions

1.1 Recipients

1.1.1 Healthcare Professionals (HCP)

Any natural person who is a member of a medical, dental, pharmaceutical, or other healthcare profession and who, in the course of their professional activities in the reporting country, is authorized to prescribe, sell, supply, recommend, or administer prescription drugs.

1.1.2 Healthcare Organizations (HCO)

Any legal entity or organization with a registered office or permanent place of business in the reporting country that is a healthcare, medical, or scientific institution or association, regardless of its legal or organizational form, as well as any legal entity through which one or more healthcare professionals provide services.

1.1.3 Patient Organizations (PO)

Patient organizations are organizations that represent the interests of patients or patient groups within the healthcare system. Disclosures to patient organizations are not included in this transparency report and are published separately in a dedicated report.

1.1.4 Treatment of Retired and Deceased HCPs

Disclosures are made for all healthcare professionals who received a grant during the reporting period, including those who have since retired or passed away. The disclosure reflects the status at the time of the interaction.

1.2 Type of Disclosures

1.2.1 Donations and Grants

Financial contributions to support:

- Medical or scientific research
- Medical or scientific education
- Health programs aimed at improving health outcomes (e.g., disease prevention)
- Scholarships and fellowships.

1.2.2 Sponsorship Agreements

For events organized by third parties (e.g., professional conference organizers, medical and scientific societies), Blueprint Medicines may enter into sponsorship agreements covering the following:

- Company-sponsored satellite symposia featuring scientific presentations
- Booth rental for the provision of scientific information upon request by healthcare professionals (HCPs)
- Sponsorship of speakers or faculty members (selected by the event organizer, without Blueprint Medicines influence)
- Sponsorship of educational/training courses (participant selection independent of Blueprint Medicines)
- Advertising space (print, electronic, banners, or other formats).

1.2.3 Contribution to Event Costs

Events include all scientific or educational gatherings (e.g., congresses, conferences, symposia, advisory boards, training sessions) organized by or on behalf of Blueprint Medicines, including hospitality where permitted. Most events are managed by third parties (e.g., convention agencies, travel agencies) under service agreements. These include participant lists and related benefits.

1.2.4 Fees for Services and Consulting

Blueprint Medicines regularly engages external experts to provide services in medical or scientific fields.

Services include:

- Speaking at or chairing scientific meetings
- Participation in panels and committees
- Training and medical education
- Consulting

All agreements are documented in written contracts that detail the purpose, rationale, and services to be provided prior to the provision of services.

1.2.5 Additional Expenses Related to Contracts

The expenses associated with the contracts, which are agreed upon in the fees for service or consulting contracts, cover costs for lodging and transportation—excluding meals and beverages—incurred by the expert while performing the service.

2 Scope of Disclosure

2.1 Products Covered

The disclosure covers prescription-only medicines (POM) in accordance with the EFPIA Transparency Code.

2.2 Company Covered

Blueprint Medicines (Germany) GmbH

2.3 Excluded Benefits

The following benefits are excluded from disclosure: informational and educational materials of negligible value, meals and beverages within permitted limits, commercial discounts and rebates, and drug samples.

2.4 Date of the benefits

Depending on the type (direct or indirect) and nature (cash or in-kind) of the benefits, two conventions are applied:

- Direct benefits: The date corresponds to the date of transfer to the recipient's bank account.
- Event-related benefits: For benefits related to an event (e.g., conference registration, flights, hotel), all payments are recorded on the first day of the event.

2.5 Direct Benefits

Benefits provided directly by Blueprint Medicines to a recipient.

2.6 Indirect benefits

Benefits provided on behalf of Blueprint Medicines to a recipient, or benefits provided through an intermediary (i.e., a third party) where Blueprint Medicines knows or can identify the covered recipient who will benefit from the benefit.

2.7 Non-monetary benefits

A non-monetary benefit refers to any benefit granted to a covered recipient without a direct cash payment. Examples include travel and lodging expenses for conference attendance, registration fees for educational events, and other in-kind benefits.

If the benefit is provided through a third party (e.g., an event organizer), the value is attributed to the recipient and disclosed under the recipient's name.

2.8 Benefits Related to Attendance, Cancellation, and Refunds

No-shows and last-minute cancellations are not disclosed, as no specific benefit is provided to the HCP.

2.9 Cross-Border Activities

Cross-border payments to recipients are disclosed in accordance with applicable transparency regulations, with the reporting obligations assigned to the subsidiary in the recipient's country of practice.

2.10 R&D

Grants related to research and development activities are disclosed exclusively on an aggregated basis and are not subject to individual disclosure. Retrospective non-interventional studies are also included in the aggregated R&D category, as they follow the same processes and ethical standards as prospective studies.

2.11 Voluntary Disclosure

Not applicable

3 Special Considerations

3.1 Country-Specific Identifier

Blueprint Medicines uses internal and external identifiers to ensure that each payment is accurately assigned to the correct covered recipient.

3.2 Self-Employed HCPs

If a healthcare professional provides services through a self-employed entity, the disclosure is made under the name of the individual healthcare professional.

3.3 Multi-Year Agreements

Multi-year agreements encompass a series of services or sponsored activities/events that span multiple years. Transfers of value related to these agreements are disclosed in accordance with the relevant reporting period.

3.4 Country-Specific Characteristics

3.4.1 Cross-Border Payments

Cross-border payments are reported in the country where the recipient has their primary registered address or principal place of business, in accordance with the applicable EFPIA disclosure principles.

3.4.2 Aggregated vs. Individual Disclosure

Aggregation is applied beyond that required for research and development grants due to lack of consent from HCPs, HCOs and POs. All other grants are disclosed on an individual basis, where applicable.

3.4.3 Consent to Individual Disclosure

Consent is not sought prior to disclosure. Recipients are not informed in advance and given the opportunity to consent to the disclosure of grants. See 3.4.2. and 4.1.

3.5 Quality Checks

Blueprint Medicines applies strict quality controls to ensure, to the best of its knowledge, accuracy and compliance prior to disclosure. These include validating recipient details, verifying grants, reviewing reporting categories, confirming consent, and conducting an internal review and certification prior to publication.

4 Legal Basis for Data Protection

4.1 Declaration of Consent for Individual Disclosure

For disclosure purposes, Blueprint Medicines implements a consent process for recipients of benefits who are subject to data protection requirements.

Consent is requested in writing from the relevant recipients prior to disclosure. Where consent is granted, grants are disclosed on an individual basis, including the recipient’s name, address, and the specific grants received.

Where consent is not granted or no response is received, payments are disclosed only in aggregate form.

To ensure consistency and avoid any distortion of the transparency data disclosed on an individual basis, Blueprint Medicines does not allow partial consent. Recipients may therefore either consent to the disclosure of all relevant grants or completely refuse individual disclosure.

Recipients subject to data protection requirements may withdraw their consent at any time by providing notice. In the event of a withdrawal of consent, all payments relating to the recipient will be removed from the individual disclosure and subsequently included in the aggregated disclosure.

4.2 Legitimate Interest

Not applicable

5 Form of Disclosure

5.1 Publication Date

The transparency report is published annually after the end of the reporting year. Publication takes place by June 30 of the year following the relevant reporting period.

5.2 Disclosure Platform

The transparency report is published on the Global Corporate Blueprint Medicines' website. Where applicable, the report may also be made available via a link on a central industry transparency platform.

5.3 Language of Disclosure

The transparency report is published in German or English.

6 Financial Disclosure Data

6.1 Currency

Local grants are always recorded in the currency of the recipient covered by the report.

6.2 Value-Added Tax (VAT) Included or Excluded

All amounts disclosed as grants are reported on a gross basis, including value-added tax (VAT) where applicable.

6.3 Calculation Rules

Blueprint Medicines applies the following calculation principles for payments:

• Indirect payments: For payments made through third parties or Blueprint Medicines subsidiaries outside the reporting country, it is not

always known whether the amounts include VAT or are exclusive of VAT. Additionally, information on the payment date is not always available.

• Currency conversion: When payments are made in different currencies, the conversion is based on the exchange rate at the time of payment or a standard monthly corporate rate.

• Rounding: All disclosed amounts are rounded to two decimal places using standard rounding rules.

• Event-related costs: For multi-part events (e.g., travel, lodging, registration), all costs are aggregated under the first day of the event (in accordance with the EFPIA convention).

7 Additional Information

7.1 Advance Notification to HCPs

A prior notification procedure could not be carried out in accordance with applicable requirements.

Therefore, recipients could not receive advance notice and thus have not had the opportunity to review their data prior to publication.

7.2 Protection of Personal Data

Blueprint Medicines is committed to protecting the personal data of HCPs and complies with applicable data protection laws and regulations. HCPs are informed that they may at any time request information about their personal data stored by Sanofi and request that it be corrected or deleted.

7.3 Who should be contacted with questions about this report?

For further information regarding this report, please contact:
GlobalTransparency *GlobalTransparency@sanofi.com*